Associate Director, Patient and Health OutcomesBioMarin Pharmaceuticals Inc.Novato, California, United States
OC 20.2 - Gene Therapy in Hemophilia A: the Impact of Valoctocogene Roxaparvovec on Patient Outcomes – Initial Results from Patient Reported Outcomes, Burdens and Experiences (PROBE) from the GENEr8-1 Trial
Sunday, June 25, 202315:00 – 15:15 ET
